Please ensure Javascript is enabled for purposes of website accessibility

Why an FDA Approval Caused Sorrento Therapeutics' Pain

By Brian Orelli, PhD - Updated Mar 1, 2018 at 6:54PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A sell-the-news 24% drop. Oh my!

What happened

Sorrento Therapeutics (SRNE -2.17%) fell 24% today after announcing after the bell yesterday that the FDA approved its ZTlido lidocaine topical system for the treatment of pain associated with post-herpetic neuralgia, also referred to as post-shingles pain.

So what

FDA approvals are supposed to make companies worth more, not less, but this seems to simply be a case of "sell the news," given the massive run-up shares of Sorrento have had over the last two months as investors anticipated an approval.SRNE Chart

SRNE data by YCharts.

ZTlido is designed to be a better version of Lidoderm, a lidocaine patch already on the market. It's designed to stay on longer and deliver more of the lidocaine in the product, but since it has the same active ingredient, there was little concern that the FDA would fret about the efficacy and safety of ZTlido. About the only thing investors had to worry about was whether the FDA would find issues with the manufacturing part of the marketing application, but that clearly wasn't an issue.

Paper reading Diagnosis: Shingles with medication, stethoscope, and glasses on it

Image source: Getty Images.

Now what

Now investors have to worry about how well ZTlido will compete with Lidoderm, which has been on the market since 1999. Two decades is a long time to change doctors' prescription habits. And since there are generic versions of Lidoderm, there may be issues with Sorrento getting ZTlido coverage by insurers with copays that patients are willing to pay.

Sorrento has hinted that it may spin off ZTlido and the related technology, which could be used to deliver other active ingredients. If it was done as an IPO -- as opposed to giving current shareholders a stake in the new company -- the spinoff could result in some much needed cash to fund development of Sorrento's pipeline of chimeric antigen receptor T-cell therapies that can treat a variety of cancers, which are much more promising -- and what investors should be focused on.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
$2.71 (-2.17%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.